- CITATIONS: 1
|Application ||WB, IHC-P, E|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||22142 Da|
|Antigen Region||123-150 aa|
|Other Names||Visinin-like protein 1, VILIP, VLP-1, Hippocalcin-like protein 3, HLP3, VSNL1, VISL1|
|Target/Specificity||This VILIP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 123-150 amino acids from the C-terminal region of human VILIP1.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||VILIP1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Regulates (in vitro) the inhibition of rhodopsin phosphorylation in a calcium-dependent manner.|
|Tissue Location||Brain and retina. Neuron-specific in the central and peripheral nervous system. Increased in the cerebrospinal fluid of Alzheimer disease patients (at protein level).|
Provided below are standard protocols that you may find useful for product applications.
The visinin and visinin-like peptides represent a family of calcium-binding proteins that are highly expressed in the retina. Visinin has been shown to be a cone cell-specific protein with a molecular weight of 24 kDa. Several members of the visinin family of genes have been isolated and characterized from different species. These peptides are believed to be involved in the processes of phototransduction. The recoverin gene (RCV1) is believed to be involved in the pathophysiology of retinopathy in cancer patients.
Braunewell, K.H., et al., Neuropharmacology 44(6):707-715 (2003). Lin, L., et al., J. Biol. Chem. 277(44):41872-41878 (2002). Spilker, C., et al., J. Neurosci. 22(17):7331-7339 (2002). Bernstein, H.G., et al., Neuroreport 13(4):393-396 (2002). Lin, L., et al., Biochem. Biophys. Res. Commun. 296(4):827-832 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.